Evidence map›Paper›PMID 31983017›Full record

ArticleBreast cancer research and treatment2020

The novel TP53 3'-end methylation pattern associated with its expression would be a potential biomarker for breast cancer detection.

Feng Zeng, Jianfu Heng, Xinwu Guo, Yue Wang, Wenhan Wu, Lili Tang, Min Chen, Shouman Wang, Hongyu Deng, Jun Wang

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Feng ZengDepartment of Emergency, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Jianfu HengHunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, 410013, China.
Xinwu GuoSansure Biotech Inc., Changsha, 410205, Hunan, China.
Yue WangSchool of Life Sciences, Central South University, Changsha, 410013, Hunan, China.
Wenhan WuSchool of Life Sciences, Central South University, Changsha, 410013, Hunan, China.
Lili TangDepartment of Breast Surgery, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Min ChenSansure Biotech Inc., Changsha, 410205, Hunan, China.
Shouman WangDepartment of Breast Surgery, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Hongyu DengHunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, 410013, China.
Jun WangSchool of Life Sciences, Central South University, Changsha, 410013, Hunan, China. junwang@csu.edu.cn.ORCID http://orcid.org/0000-0001-8008-4563
Central South University · CNSansure Biotech (China) · CNHunan Cancer Hospital · CN

Funding

Natural Science Foundation of China No. 81272296 and 81372228Natural Science Foundation of China No. 81802814Natural Science Foundation of Hunan Province National Health Commission No. C2019083Natural Science Foundation of the Science and Technology Bureau of Changsha, China Major Special Projects No. K1204017-31 and K1306011-31, General Program No. kq1801108Scientific Project of China Hunan Provincial Science and Technology Department No. 2012SK2013
6 · The paper itself

Abstract

backgroundDeficiency or silence of TP53 is an early event in breast tumorigenesis. Aberrant methylation and mutation in regulatory regions were considered as crucial regulators of gene expression.

methodsUsing multiplex-PCR and next-generation sequencing technology, we analyzed TP53 mutation spectrum in its promoter region. Using PCR target sequence enrichment and next-generation bisulfite sequencing technology, we analyzed the methylation profile of the promoter and 3'-end regions of TP53 gene in paired breast tumor and normal tissues from 120 breast cancer patients. The expression of TP53 and the flanking gene ATP1B2 was explored with qPCR method in the same cohort.

resultsNo promoter mutation of TP53 gene was found in the cohort of the 120 breast cancer patients. The 3'-end of TP53 gene was hyper-methylated (average 78.71%) compared with the promoter region (average less than 1%) in breast tumor tissues. TP53 was significantly lower expressed (P = 1.68E-15) and hyper-methylated in 3'-end (P = 1.82E-18) in tumor. Negative cis correlation was found between the TP53 expression and its 3'-end methylation (P = 9.02E-8, R = 0.337). TP53 expression was significantly associated with PR status (P = 0.0128), Ki67 level (P = 0.0091), and breast cancer subtypes (P = 0.0109). TP53 3'-end methylation and expression showed a good performance in discriminating breast cancer and normal tissues with an AUC of 0.930.

conclusionsThe 3'-end methylation of TP53 might be a crucial regulator for its expression in breast cancer, suggesting that TP53 3'-end hyper-methylation associated with its lower expression could be a potential biomarker for breast cancer diagnosis.

Indexed as

3' Untranslated RegionsBiomarkers, TumorDNA MethylationGene Expression Regulation, NeoplasticAdenosine TriphosphatasesAdultAgedBreast NeoplasmsCation Transport ProteinsCell Adhesion Molecules, NeuronalCpG IslandsFemaleHigh-Throughput Nucleotide SequencingHumansMiddle AgedMutation3' Untranslated RegionsAdenosine TriphosphatasesATP1B2 protein, humanBiomarkers, TumorCation Transport ProteinsCell Adhesion Molecules, NeuronalTP53 protein, humanTumor Suppressor Protein p53ATP1B2Breast cancerIntergenic methylationNext-generation sequencingTP53

Identifiers

PMID31983017
OpenAlexW3000828683

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.